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Abstract: Fragile X syndrome (FXS) is the most common inherited form of intellectual disability (ID)
and a known monogenic cause of autism spectrum disorder (ASD). It is a trinucleotide repeat disorder,
in which more than 200 CGG repeats in the 5’ untranslated region (UTR) of the fragile X mental
retardation 1 (FMR1) gene causes methylation of the promoter with consequent silencing of the gene,
ultimately leading to the loss of the encoded fragile X mental retardation 1 protein, FMRP. FMRP is
an RNA binding protein that plays a primary role as a repressor of translation of various mRNAs,
many of which are involved in the maintenance and development of neuronal synaptic function and
plasticity. In addition to intellectual disability, patients with FXS face several behavioral challenges,
including anxiety, hyperactivity, seizures, repetitive behavior, and problems with executive and
language performance. Currently, there is no cure or approved medication for the treatment of the
underlying causes of FXS, but in the past few years, our knowledge about the proteins and pathways
that are dysregulated by the loss of FMRP has increased, leading to clinical trials and to the path
of developing molecular biomarkers for identifying potential targets for therapies. In this paper,
we review candidate molecular biomarkers that have been identified in preclinical studies in the FXS
mouse animal model and are now under validation for human applications or have already made
their way to clinical trials.
Keywords: fragile X syndrome; molecular biomarkers; FMR1; FMRP; intellectual disability; Fmr1 KO
mouse; ASD
1. Introduction
A biomarker is “a characteristic that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention” [1]. Biomarkers can be found in blood, plasma, or other tissues and are generally viewed
as a molecular signature able to identify individuals who are at high risk for a specific condition.
They can also be detected before disease symptoms and therefore used to predict the occurrence of
a condition or the nature and severity of disease outcomes in an individual. Importantly, they can be
used to evaluate the efficacy of response to pharmacological intervention.
Fragile X syndrome (FXS) is the most prevalent inherited cause of intellectual disability and
the single leading monogenic known cause of autism, as 60% of those with a full mutation present
with autism spectrum disorder (ASD) [2]. The clinical symptoms include anxiety, impairment in
cognitive, executive and language performance, hyperactivity, impulsivity, insomnia, seizures and
physical features such as hypotonia, flat feet, hyperextensible joints, and macroorchidism [3]. FXS is
caused by the abnormal expansion, greater than 200 units of a naturally occurring CGG repeat in
the 5’ untranslated region (UTR) of the fragile X mental retardation 1 (FMR1) gene, located on the X
chromosome. This expansion, named full mutation, results in hypermethylation and transcriptional
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silencing of the gene, leading to the loss or reduction of fragile X mental retardation 1 protein (FMRP)
expression and to the diagnosis of fragile X syndrome [4–6]. Individuals carrying expansion of 55–200
CGG repeat are premutation carriers and at risk of developing the late-onset neurodegenerative
syndrome, fragile X-associated tremor/ataxia syndrome (FXTAS), the fragile X-associated primary
ovarian insufficiency (FXPOI) [7] and the fragile X-associated neuropsychiatric disorders (FXAND) [8].
FMRP is an RNA-binding protein and a translational regulator, whose function affects synaptic
plasticity, spine morphology, and several cellular signaling pathways. Reduced expression of FMRP
leads to the abnormalities in neurodevelopmental processes and the disturbed neuronal communications
observed in FXS [9]. Young adults and adolescents with FXS show neuroanatomical abnormalities [10],
and the regions of the brain that are significantly impacted by the loss of FMRP are the hippocampus
(a structure that plays a critical role in the learning and memory and the regulation of mood and
cognition [11]), the cerebellum, and the basal forebrain (nucleus basalis) [12]. Several studies in the
Fmr1 knockout (KO) mouse model suggest that FMRP plays a critical role during specific periods
of cortical development with regional brain volume changes occurring in adult mouse brain [13,14].
Brain volume changes have also been observed in children with FXS, specifically in the temporal lobe,
cerebellum, caudate nucleus, and amygdala regions of the brain [15,16].
FMRP function appears to be mostly inhibitory as it prevents the activity of various biochemical
pathways in a “controlled” manner [17]. In a sense, reduced FMRP leads to exaggerated or reduced
biochemical reactions that can adversely affect neural function. The past two decades of research have
shown defects in the central excitatory glutamatergic and inhibitory GABAergic pathways and in several
other neurotransmitter systems including serotonin and dopamine [18,19]. Thus, the development of
molecular measures that reflect the impact of a drug on one or more of the FMRP-regulated pathways
(Figure 1), including the activity or the expression level of proteins in the translational activation pathway
and particularly of those regulated by FMRP, could potentially act as molecular biomarkers for FXS.
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Figure 1. Potential therapeutic targets for fragile X syndrome (FXS). Diagram of the mechanisms
implicated in FXS leading to altered synaptic plasticity. The figure also shows the molecular pathways
targeted or understudy, for the reversal of cognitive and behavioral impairments in FXS patients. Several
typ s of drug , modulators, and compounds (inhibitor, agonist, and antagonist) can interfere with
different pathways disturbed in FXS and have been used in a number of pharmacological treatments
some of which are currently under investigation and re indicated in the figure.
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The Fmr1 knockout (KO) mouse model [20], lacks a functional FMR1 gene and therefore does not
express FMRP. Many studies have shown that the Fmr1 KO mouse presents with some phenotypes that
resemble the human disorder, including biochemistry [21], electrophysiology [22], neuropathology [23],
and spine morphology [24]. Although the observed patterns of brain activity, including audiogenic
seizures, are similar to those in individuals affected by FXS [25], these mice poorly mimic human
behavior. Indeed, the strains of the Fmr1 KO mouse that are often used to test drugs for FXS do not
show the cognitive problems seen in patients with FXS [26]. Nevertheless, a large body of literature on
the Fmr1 KO mouse has paved the way to preclinical studies which have shown to rescue several of
the FXS phenotypes [27] and have ultimately led to clinical trials in patients with FXS.
Hope has been tempered by the lack of translating the positive results observed in the Fmr1
KO mouse model into therapy in a clinical setting. Currently, nonpharmacological and behavioral
treatments are symptomatic, and they can be coupled with pharmacological treatments of anxiety,
aggression, and attention deficit hyperactivity disorder (ADHD).
To date, there is no cure for FXS, and the recent failures of multiple clinical trials have highlighted
the need for the development and validation of new biomarkers to better measure the clinical outcome
of these treatments [28,29]. Many studies aimed to a better understanding of the underlying molecular
mechanisms and pathways involved in FXS have led to the development of specific biomarkers for
defining targeted therapeutic strategies intended to reverse the intellectual and behavioral problems
of patients with FXS. In this paper, we will review the proposed candidate molecular biomarkers
(Figure 2) that have been identified in Fmr1 KO mouse as an early sign of drug promise and in some
cases, later moved to a clinical trial in patients with FXS.
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Figure 2. Candidate molecular biomarkers for FXS include a number of targets and substrates of
several signaling pathways, in addition to fragile X mental retardation 1 (FMR1) molecular measures and
metabolites, of which expression levels or activity have been found dysregulated in FXS animal models
and in human FXS tissues. Fmr1 mRNA and fragile X mental retardation 1 protein (FMRP) expression, de
novo protein synthesis, γ-aminobutyric acid (GABA) receptors (GABAA and GABAB), phosphoinositide
3-kinase (PI3K), extracellular-regulated kinase (ERK), matrix metalloproteinase-9 (MMP-9), brain-derived
neurotrophic factor (BDNF), mammalian target of rapamycin (mTOR), p70 ribosomal S6 kinase (S6K1),
ion channels (KNa, BKCa, CaV, Kv, HCN1), bone morphogenetic protein receptor Type 2 (BMPR2),
Diacylglycerol Kinase Kappa (Dgkκ), endocannabinoid system (eCS), amyloid-β pr tein precursor (APP),
microRNA’s (miRNA’s), st iatal-enriched protein tyrosine phosphata e (STEP), glycogen sy thase kinase-3
(GSK-3) cytokine and chemokine profiles, metabotropic glutamate receptor (mGluRs).
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2. FMR1 Molecular Measures
FMR1-related measures, including CGG repeat number, percent of methylation, FMR1 mRNA
and FMRP expression levels have been correlated to neurocognitive and social–affective functioning
assessments and mental health problems in individuals with FXS [30–38]. The magnitude of the
observed correlations generally suggests that these molecular biomarkers are likely accounting only
for a proportion of the phenotypic variability of this disorder.
Variation in CGG repeat size and methylation, so-called mosaicism, could be a useful biomarker
of various types of risks that could affect subjects with FXS. Mosaicism defines differences in gene
expression between those with fully hypermethylated FMR1 alleles and those carrying unmethylated
alleles, and ultimately reflects the levels of expression of FMR1 mRNA and FMRP. Generally, mosaicism
refers to the presence of a full mutation allele(s) and a premutation allele (size mosaicism) or the
presence of a full methylated allele(s) and unmethylated alleles (methylation mosaicism), throughout
the CGG repeat size range.
Sex differences undoubtedly contribute to the severity of the FXS phenotype; indeed, intellectual
and developmental disability is observed in 85% of males and only in 25% of females [27,39,40].
In females, who have two X chromosomes, the process of X inactivation, early during embryonic
development, leads to methylation and therefore inactivity of one X chromosome in each cell.
However, due to the presence of the chromosome carrying the normal allele, the impact of the FMR1
mutation in females is reduced relative to males, who have only one X chromosome [41]. The relative
proportion of the normal allele on the active and inactive X chromosomes, so-called activation ratio
(AR), has shown to contribute to differences in affectedness among females, making the AR a useful
biomarker for determining the severity of the phenotype. It should be noted that since X inactivation
is a random process, it could be different in different tissues, such as blood and brain [42–44].
3. Metabotropic Glutamate Receptors (mGluRs)
The “mGluR theory of FXS” states that the absence of FMRP leads to excessive metabotropic
glutamate receptors (mGluRs, mGluR1 and mGluR5) activated long-term depression (LTD) and
reduced responsiveness to signals in the hippocampus and other parts of the brain involved in
memory and learning. Together, they are contributing to the neurological and psychiatric symptoms of
FXS [45–47]. Reduction of mGluR signaling has demonstrated a reversal of the fragile X phenotypes
providing substantial support to the involvement of the mGluR5 pathway in FXS [48]. For more than
a decade, our understanding of the molecular pathophysiology of FXS has been substantially advanced
by the corroboration of “mGluR theory of FXS” in a wide range of experiments with a number of
different mGluR5 inhibitors tested in both the Fmr1 KO mouse [49–53] and in the Drosophila models
of FXS [54–62]. Fmr1 mutant mouse with a 50% reduction in mGluR5 expression was generated to
demonstrate that a range of FXS phenotypes could be corrected by downregulating signaling through
group 1 mGluRs [45]. Their findings showed that the decrease in mGlu5 expression levels from
early embryonic development effectively prevented the onset of a broad range of FXS phenotypes,
including audiogenic seizures, increased basal protein synthesis, spine density, although no effect on
macroorchidism was observed.
MPEP (2-methyl-6-phenylethynyl-pyridine) was the first mGluR5-antagonist tested in the Fmr1
KO mouse, which demonstrated rescue of behavioral defects, including open field performance [63],
the rescue of the spine/filopodia ratio in Fmr1 KO neurons to the levels observed in wild-type
neurons [64]. Further, MPEP treated Fmr1 KO mouse showed improved behavior by significantly
fewer errors, less perseveration, and impulsivity when navigating mazes, in addition to reverse
postsynaptic density-95 (PSD-95) protein deficits which, if confirmed, could be considered a molecular
biomarker [65]. Finally, MPEP prevented an abnormal clustering of DHPG (group I mGluR agonist
(S)-3,5-dihydroxyphenylglycine) responsive cells (responsible for activation of ionotropic receptors in
mouse FXS neurospheres) and corrected morphological defects of differentiated cells [66].
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Similarly, a study on chronic treatment of Fmr1 KO mouse with the long-acting mGlu5 inhibitor
2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl) pyridine (CTEP),
fully corrected numerous phenotypes including the increased synaptic spine density, protein synthesis
rate, aberrant synaptic plasticity, learning and memory deficits, increased body growth rate,
and sensitivity to audiogenic seizures. In addition, this study shows a reduction of both extracellular
signal-regulated kinase (ERK) activity and mTOR phosphorylation levels in the Fmr1 KO but not
in wild-type (WT) animals, suggesting that they could represent potential biomarkers in FXS [53].
These studies have shown that the long-term, uninterrupted mGluR5 inhibition is essential for a
successful pharmacological intervention as a single dose of the mGluR5 inhibitors was not sufficient
to correct the mouse phenotypes. [50,53]. One of the potential molecular mechanisms for mGluR5
dysfunction in FXS is the decreased association of mGluR5 with the Homer family of scaffolding
proteins. Indeed, genetic deletion of H1 (an activity-inducible isoform of Homer1) restored regular
mGluR5-long Homer association in the Fmr1 KO and corrected much of the mGluR5 dysfunction as
well as behavioral phenotypes, including anxiety and audiogenic seizures [67]. Further, the disruption
of mGluR5-Homer resulted in phenotypes of FXS including reduced mGluR5 association with the
postsynaptic density, deficits in agonist-induced translational control, protein synthesis-independent
LTD, neocortical hyperexcitability, audiogenic seizures, and altered behaviors, such as anxiety and
sensorimotor gating [68].
The Drosophila genome encodes only a single mGluR (DmGluRA), compared to the eight separate
receptors in mammals [69]. The simplicity of the Drosophila system, coupled with the evolutionary
conservation of the activation pathways, has provided an excellent model to test the mGluR hypothesis.
Treatment with lithium and MPEP restored normal courtship behavior, mushroom, body defects,
and short-term memory, but not β-lobe crossing, suggesting that other morphological abnormalities
are responsible for the memory defects [54,70].
Molecular analyses reveal an inverse relationship between dFMRP and DmGluRA, with the
latter overexpressed in dFmr1 null animals and dFMRP overexpressed in DmGluRA nulls [57].
The DmGluRA null also shows more striking defects in activity-dependent synaptic function, including
high transmission amplitudes during high-frequency stimulation and abnormally strong hyper
potentiation following high-frequency stimulation [57,58]. The successful unbiased screen for small
molecules that can rescue the lethality of glutamate-treated larvae and adults dFmr1 mutants, using the
mGluR5 noncompetitive antagonist MPEP or LiCl has been reported to rescue naïve courtship behavior,
immediate recall memory, and short-term memory of dFmr1 mutants [56,59]. The compelling results
of these preclinical studies, showing evidence of benefits in rodent and Drosophila disease models,
have prompted the application of mGlu5 inhibitors as potential target treatments in human clinical
trials for FXS. Thus, clinical trials in FXS patients have been conducted to explore the safety, tolerability,
and efficacy of a number of different mGluR5 antagonists.
Fenobam [71], the first mGlur5 antagonist drug evaluated in a single-dose open-label study
of 12 male and female adults with FXS (mean age 23.9 years), showed trends of improvement in
a prepulse inhibition deficit relative to controls who did not receive the drug [72]. Subsequently,
in an exploratory study, the efficacy of mavoglurant (AFQ056) [73] was tested in a randomized
double-blind crossover study of 30 FXS males. In this study, seven patients with a hypermethylated full
mutation with no detectableFMR1mRNA expression, improved stereotypic behavior, hyperactivity, and
inappropriate speech, while no improvement found in 18 patients with partial promoter methylation [74].
Thus, it appears that those with full methylation responded best, whereas those who were mosaics
with partial methylation had a variable response with a lack of overall efficacy in that group.
Although methylation is often regarded as a biomarker, results to date do not explain why some of
those with lack of methylation responded and others did not [74]. In addition, the reported behavioral
effects of stereotypic behavior, hyperactivity, and inappropriate speech were not replicated with FXS
male and female adolescents and adults either full or partial FMR1 methylation in subsequent 12-week
double-blind mavoglurant studies [75].
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Similarly, extensive proof of concept study was conducted with basimglurant, a potent and
selective mGluR5-negative allosteric modulator (NAM) [76,77] and mavoglurant in male and female
adults with FXS. In spite of their promising results in preclinical studies [77–80] these studies ended
because no improvement in the clinical phenotype of patients enrolled in the clinical trials using
these modulators were observed [29,81,82]. Recently, in a phase 2 12-weeks double-blind clinical
trial, basimglurant did not demonstrate improvement over placebo in a parallel-group study of
183 adults and adolescents (aged 14–50, mean 23.4 years) with FXS [83]. Later, the study reported the
long-term safety and efficacy of mavoglurant in the two open-label extensions in adolescent (n = 119,
aged 12–19 years) and adult (n = 148, aged 18–45 years). In both studies, mavoglurant was well
tolerated, and moderate behavioral improvements were observed in FXS as compared to the placebo
control group. Thus, the compelling preclinical evidence for the therapeutic potential of mGlu5
inhibitors in the mouse and the Drosophila disease models has not translated in the anticipated benefits
and improvement of the phenotype in FXS patients [84].
4. γ-Aminobutyric Acid (GABA) Receptors
GABA is the most prominent inhibitory neurotransmitter that acts through three receptors
in the brain. GABAA receptors are ligand-regulated chloride channels that upon activation cause
hyperpolarization in mature neurons; GABAB receptors are heterodimeric G protein-coupled receptors
(GPCRs) which are mostly expressed presynaptically in the brain; and, GABAC is CYS-loop ligand-gated
ion channels receptors with a similar pentameric structure to GABAA but are homomeric. FMRP
directly binds several GABAA receptor (α1, α2, α3, δ, and γ2) mRNAs of which expression is reduced
in the cortex and cerebellum of young Fmr1 KO mouse. Thus, the mRNA expression level of these
subunits could be used as biomarker; however, they have not been studied in clinical trials for FXS
with any GABA agonists [85]. The introduction of a yeast artificial chromosome (YAC) containing the
“healthy” human FMR1 genomic region into Fmr1 KO mouse rescued the expression of these specific
subunits of GABAA receptors [86]. A recent electrophysiological study supported the notion that the δ
subunit of the aminobutyric acid type A receptors (GABAARs) is compromised in the Fmr1 KO mouse,
by reporting a 4-fold decrease in tonic inhibition [87].
The delay in switching from depolarizing to hyperpolarizing GABA has also been observed
in the cortex of Fmr1 KO mouse during development [88]. Moreover, the oxytocin-mediated,
GABA excitation–inhibition shift that occurs in newborn rodents during delivery is absent from the
hippocampal neurons of Fmr1KO mouse. As a result, the hippocampal neurons have elevated intracellular
chloride levels, increased excitatory GABA, enhanced the glutamatergic activity, and elevated gamma
oscillations [89].
In a study, the response of the FXS neurons (differentiated in vitro from human embryonic stem
cells lacking synaptic activity) has been investigated by pulse application of the neurotransmitter GABA.
The results confirmed that human FXS neurons do not respond to GABA as FMRP plays a role in the
development of the GABAergic synapse during neurogenesis, and that might be one of the potential
reasons of the observed default synaptic activity in FXS patients. [90]. Some GABA agonists have
been used in the Fmr1 KO mouse to rescue behavioral abnormalities. The primary neuron excitability
deficits in the amygdala of the Fmr1 KO mouse was restored by gaboxadol (THIP), a GABAA receptor
agonist, which also improved some specific behavioral characteristics, including hyperactivity and
auditory seizures [91]. The treatment of the Fmr1 KO mouse with bumetanide (specific NKCC1 chloride
importer antagonist) normalized electrophysiological abnormalities in the mutant offspring as well
as hyperactivity and autistic behaviors [89]. Finally, arbaclofen, a GABAB agonist, improved protein
synthesis, the abnormal auditory-evoked gamma oscillations, working memory and anxiety-related
behavior in Fmr1 KO mouse [92–94].
Thus, these findings from different studies in the FXS animal models confirmed that GABA
receptors are suitable targets for target treatment in FXS [18,39,95–103]. Indeed, two phase 3
placebo-controlled trials were conducted (with subjects aged 12–50 and in subjects aged 5–11) to
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determine the safety and efficacy of arbaclofen for improving social behavior in FXS patients. Although,
arbaclofen did not meet the primary outcome measures of improved social avoidance in FXS in either
study [104], in a double-blind placebo-controlled crossover trial [105], improved social function and
behavior were reported in FXS patients. Acamprosate, which activates GABAB and GABAA receptors,
also improved several phenotypes like cortical upstate duration, behavioral improvement, anxiety,
locomotor tests in Fmr1 KO mouse and reduced ERK1/2 activation in brain tissue [106]. Acamprosate
has also been tested in an open-label 10-week trial of 12 young children aged 6–17 years with FXS. It was
found safe and well-tolerated and resulted in better social behavior and reduced hyperactivity [107].
Ganaxolone is a neurosteroid and a positive GABAA modulator that rescued several phenotypes in
the Fmr1 KO mouse, like increased marble-burying assay, sensory and sensorimotor gating in the
acoustic startle response, and prepulse inhibition [86]. Tested in a recent randomized double-blind
placebo-controlled crossover trial in children with FXS, aged 6–17, years, ganaxolone was found to
be safe and have beneficial effects in some patients, particularly for those with higher anxiety or
lower cognitive abilities [108]. These preclinical and clinical studies strengthen the hypothesis of
GABA receptors involved in the pathology of FXS and as they are the major inhibitory receptors in the
brain, they point to the therapeutic potential of the GABA receptor particularly for the behavioral and
epileptic phenotypes associated with fragile X syndrome.
5. De Novo Protein Synthesis
Synaptic strength plays a crucial role in learning and memory and it is compromised in many
neurodevelopmental disorders. One of the molecular mechanisms that regulate spine morphology,
and therefore synaptic strength, is local de novo protein synthesis that enables synapses to alter their
function and structure autonomously [109]. FMRP, an RNA binding protein which acts as a translational
repressor of many synaptic proteins, is crucial in regulating this process, and the partial or complete
lack of FMRP in FXS leads to increased protein translation at the synapses. The metabotropic glutamate
receptor subtype 5 (mGluR5) theory of FXS also indicate that the imbalance of mechanisms involved in
synaptic shaping and protein translation are responsible for many of the symptoms observed in FXS
patients [49]. The lack of FMRP also leads to a loss of translational control and to increased rates of
cerebral protein synthesis (rCPS) in some regions of the brain including the hippocampus, thalamus,
and hypothalamus of the Fmr1 KO mouse model of FXS [110].
Fibroblasts from FXS patients also showed significantly elevated rates of basal protein synthesis
along with increased levels of the phosphorylated target of rapamycin (p-mTOR), phosphorylated
extracellular signal-regulated kinase 12 (ERK1/2), and phosphorylated p70 ribosomal S6 kinase
1 (p-S6K1) [111]. Similarly, a recent study reported that the level of protein synthesis increased in
fibroblast cell lines derived from individuals with FXS and from Fmr1 KO mouse. However, this cellular
phenotype displayed a broad distribution with a proportion of individuals with FXS and in the Fmr1
KO mouse, showing a basal de novo protein synthesis within the normal range. These findings
indicate that the molecular mechanisms that control protein synthesis are the primary targets in
FXS. However, altered protein synthesis may not be the cause of all symptoms observed in FXS
and, therefore, those with normal levels of protein synthesis are not likely going to benefit from
target treatments aimed to lower protein synthesis [112]. Thus, de novo protein synthesis could be a
very useful biomarker to predict phenotypic subgroups, symptoms severity, and treatment response.
Further, as the treatment of fibroblast cells derived from FXS patients, with small molecules that block
S6K1 and phosphoinositide 3-kinase (PI3K) catalytic subunit p110β, decreased the rates of protein
synthesis in both control and patient fibroblasts; the role of these targets as a potential biomarker
should be considered [111]. FXS subjects, under propofol sedation, showed a reduced rCPS in whole
brain, cerebellum, and cortex compared to sedated controls. Similar results have been observed in most
regions examined in sedative Fmr1 KO mouse as compared to the WT mouse suggesting that changes
in synaptic signaling can correct increased rCPS in FXS [113]. Chronic dietary lithium treatment also
demonstrated to be efficacious in reversing the increased rCPS in the Fmr1 KO mouse [114].
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Some studies have shown that the mechanisms regulating the levels of protein synthesis,
can be restored by reducing the mGluR5 signaling genetically or with pharmacological
treatments [46,53,100,115–118]. Moreover, haploinsufficiency of mGluR5, reduction of MMP9,
of striatal-enriched tyrosine phosphatase (STEP) signaling, or of S6K signaling can not only restore
the levels of protein synthesis but also restore the synaptic and behavioral phenotypes in the FXS mouse
model [50,119–126]. Recently, a study showed that treatment of the Fmr1 KO mouse with a cell-permeable
peptide able to modulate ADAM metallopeptidase domain 10 (ADAM10) activity and amyloid-β protein
precursor (APP) processing, restored protein synthesis to the wild-type (WT) level [127].
These preclinical and clinical studies suggest that basal protein synthesis could be considered as
a potential biomarker and a molecular hallmark for FXS, but unfortunately, replicating this optimal
translational scenario into reality has not been fully successful [27]. The extent to which excessive
protein synthesis associated with cognitive and behavioral impairments also remained unknown.
More importantly, none of the human studies have shown an effect on the primary outcome measures
which were mainly behavioral questionnaires in children, adolescents, or adults with FXS [74,104,105].
Finally, although FMRP modulates protein synthesis, there are other factors (environmental and genetic)
that may contribute to the modulation of homeostasis of molecules involved in synaptic plasticity.
6. Phosphoinositide 3-Kinase (PI3K)
Phosphoinositide 3-kinase (PI3K) is the signaling molecule involved in cell motility, survival, growth,
and proliferation. PI3K class I catalytic subunits, p110α, p110β, p110γ, and p110δ, have their specific
dysregulation in FXS [128]. FMRP regulates the synthesis and synaptic localization of p110β, which is a
crucial signaling molecule downstream of group 1 metabotropic glutamate receptor (gp1 mGluRs) and
other membrane receptors. Lack of FMRP in the Fmr1 KO mouse leads to excess mRNA translation and
synaptic protein expression of p110β [123]. Treatment with a p110β-selective antagonist was effective in
rescuing the excess of protein synthesis in the Fmr1 KO mouse synaptoneurosomes and in lymphoblastoid
cells derived from FXS patients [123,129]. Further, a prefrontal cortex (PFC) selective knockdown of
p110β, reversed deficits in higher cognition, normalized excessive PI3K activity, restored stimulus-induced
protein synthesis, and corrected increased dendritic spine density in the Fmr1 KO mouse [130,131].
Thus, PI3K activity in patient cells might be a biomarker and could be used to assess the efficacy of drug
response in target treatment in FXS.
7. Mammalian Target of Rapamycin (mTOR) and Substrate p70 Ribosomal S6 Kinase (S6K1)
Mammalian target of rapamycin (mTOR) is a 289 kDa serine/threonine kinase protein that
controls various energetic functions at both the cellular and organism level and an essential regulator
of cell proliferation, autophagy, translation, and growth. In neuronal cells, protein synthesis
plays a fundamental role in the regulation of lasting alterations in synaptic strength or plasticity,
and of long-term potentiation (LTP), processes that are important in learning and memory [132,133].
The components of the mTOR signaling cascade, which is involved in protein synthesis-dependent
phase of synaptic strengthening, are present in dendrites suggesting a role for mTOR in local translation
and synaptic plasticity. mTOR is activated in dendrites by stimulation of group I mGluRs and it is
required for mGluR-LTD [134,135]. It has been reported that increased activity in these systems can
lead to repetitive and perseverative behavior patterns [132].
The best-characterized function of mTOR is the regulation of translation. mTOR regulates two
critical and core components of the translational initiation machinery, p70 ribosomal S6 kinase 1 and
2 (S6K1/2), and the eIF4E-binding proteins (4E-BPs), and it is also known to regulate the activity of
phosphatases such as protein phosphatase 2A (PP2A). These phosphatases, in turn, regulate mTOR
substrates, thereby generating mTOR-dependent feedback loops that control initiation rates. Increased
phosphorylation of (mTOR) substrate, p70 ribosomal subunit 6 kinase 1 (S6K1) along with the high
expression of mTOR regulator, and the serine/threonine protein kinase (Akt) was also observed in
lymphocytes and brain tissues derived from subjects with FXS [136].
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The enhanced mTOR signaling observed in the hippocampus of the Fmr1KO mouse associates with
the increase eukaryotic initiation factor complex F4 (eIF4F) [137] and with the increased phosphorylation
of the cap-binding protein eukaryotic initiation factor 4E (eIF4E) [136] to further support the increased
protein synthesis observed in FXS. These findings, in both FXS mice and humans, are consistent with
the idea that the loss of FMRP results in the dysregulation of mechanisms of translational initiation
control rather than transcriptional regulation and provide the direct evidence that mTOR dysregulation
may be useful for designing targeted treatments in FXS [136]. Therefore, targets and substrates in the
mTOR signaling pathways can act as potential molecular biomarkers. Since the molecular signaling
effects resulting from FMRP loss are likely causal in the wide-range of the severity of the FXS symptoms,
including autism, identifying the effects of FMRP loss on molecular signaling pathways, like those
governing translation, is key to advancing our ability to treat the disorder.
Finally, metformin, a type 2 diabetes medication that can improve obesity and excessive appetite,
has emerged as a candidate drug for targeted treatment of FXS based on preclinical studies. These studies
have shown rescue of a number of FXS phenotypes including memory deficits, social novelty, grooming,
dendritic spine morphology, and electrophysiology in the CA1 of the hippocampus [138,139]. Metformin
suppresses mRNA translation via inhibition of ERK and mTOR pathways, which are overactive in FXS,
supporting their potential role as molecular biomarkers, and therefore, may contribute to normalizing
signaling pathways in the CNS of FXS patients. In humans, metformin has been used in the clinical
treatment of several individuals with FXS and showed benefits not only in lowering weight gain but
also in improving language and behavior [138]. Thus, metformin shows promises for targeting several
signaling pathways disrupted in FXS and possibly rescuing some of the clinical symptoms observed in
individuals with FXS. Interestingly, a double-blind placebo-controlled trial of metformin in individuals
with FXS is currently ongoing which will assess safety and benefit of metformin in the treatment of
language deficits, behavioral problems, and obesity in individuals with FXS.
8. Extracellular-Regulated Kinase (ERK)
The ERK pathway is a chain of proteins in the cell that acts as a nodal point for cell signaling
cascades. The absence of FMRP in Fmr1 KO mouse results in rapid dephosphorylation of ERK upon
mGluR1/5 stimulation suggesting that over-activation of phosphatases in synapses affects the synaptic
translation, transcription, and synaptic receptor regulation in FXS [53,119,140,141]. Delayed early-phase
phosphorylation of ERK is observed in both neurons and thymocytes of the Fmr1 KO mouse. Likewise,
the early-phase kinetics of ERK activation in lymphocytes from human peripheral blood is also delayed
in individuals with FXS, as compared to controls [142]. The correction of the delayed ERK activation
time, resulting in a faster activation, was observed after 2 months of treatment with lithium in a pilot
open-label trial in FXS or with riluzole treatment [143,144]. These findings, based on a small number
of subjects, suggest ERK activity as a potential biomarker for measuring the metabolic status of the
disease in FXS.
Recently, the significant FMRP-dependent over-activation of ERK was observed in both FXS mouse
and humans. ERK activity was normalized in FXS platelets [145], and correlated with clinical response
to lovastatin, pointing this inhibitor of ERK pathway signaling cascade as a promising treatment for
FXS [146]. The findings by Pellerin et al. [145] suggest that the use of platelet’s ERK activity represents
a new potentially interesting biomarker for future clinical trials. It may also pave the way for other
promising and very exciting discoveries that will eventually improve FXS patients’ assessment in
future clinical trials where either lovastatin or other ERK-targeting drugs is applied.
9. Matrix Metalloproteinase-9 (MMP-9)
FMRP deficit is associated with alterations in the expression of a number of proteins, including matrix
metalloproteinase 9 (MMP-9). MMP-9 is an extracellular operating Zn2+ dependent endopeptidase that
is expressed in neurons and locally translated and released at the dendrites in response to enhanced
neuronal activity driven by glutamate. MMP-9 plays an essential role in both establishing synaptic
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connections during development and in restructuring synaptic networks in the adult brain [147]. MMP-9
mRNA is part of the FMRP complex and localizes in dendrites. Translation of MMP-9 is increased
at synapses in Fmr1 KO mice suggesting its contribution to the aberrant dendritic spine morphology
observed in the Fmr1 KO mice and in FXS patients [148,149]. The genetic disruption of MMP-9 in the
Fmr1 KO mouse rescued key aspects of Fmr1 abnormalities, including abnormal mGluR5-dependent
LTD and dendritic spine abnormalities [150], providing evidence that MMP-9 is necessary to the
development of FXS-associated defects in the Fmr1 KO mouse. Interestingly, a high level of MMP-9
has been observed in the auditory cortex of adult Fmr1 KO mice and the deletion of MMP-9 reversed
the habituation defects [151]. A decreased MMP-9 activity in the hippocampus of the Fmr1 KO mouse,
dendritic spine maturation, improvement in anxiety, and strategic exploratory behavior were observed
after treatment with the antibiotic minocycline [152]. These findings prompted the use of minocycline as
a targeted treatment in humans with FXS through open-label trials which have demonstrated benefits
with improvements in language, attention, social communication, and anxiety [153,154]. More recently,
a controlled double-blind crossover study of minocycline for FXS treatment provided evidence for the
safety of minocycline and showed benefits in global functioning in children with FXS [155]. In addition,
as expected, the higher plasma activity of MMP-9 observed in FXS patients was lowered by minocycline
in some patients [156], as minocycline is known to be a MMP-9 inhibitor [152]. On the other hand,
no changes in plasma MMP 9 activity was found after treatment with sertraline [157], a selective
serotonin-reuptake inhibitor which selectively blocks the uptake of serotonin at the presynaptic
membrane, resulting in an increased synaptic concentration of serotonin in the central nervous system
(CNS), and therefore, to an intensified serotonergic neurotransmission. Interestingly, a reduction of the
MMP-9 levels was also reported in the Fmr1 KO mouse following metformin treatment [139]. The results
of the preclinical and clinical studies indicate that minocycline, through its mechanism of action as
an MMP inhibitor, may be an additional potential effective avenue as FXS therapeutic treatment and
MMP-9 activity, a potential biomarker in FXS.
10. Brain-Derived Neurotrophic Factor (BDNF)
Brain-derived neurotrophic factor is involved in the regulation of various processes of normal
neural circuit function and development. Dysregulation in BDNF/TrkB signaling in the Fmr1 KO
mouse leads to altered brain development, including excessive sponginess, dendritic arborization [158],
and impaired synaptic plasticity [159]. These neural alterations are promoted by activity-dependent
variation in the sensitivity to BDNF-TrkB signaling, compensating postsynaptic activity [158].
The effects of reduced BDNF expression on the learning and behavioral phenotypes, including
fear conditioning, pain behaviors, and hyperactivity, was examined in the Fmr1 KO mouse crossed
with a mouse carrying a deletion of one copy of the Bdnf gene (Bdnf+/−) [160]. The authors
reported age-dependent alterations in the expression of BDNF in the hippocampus, reduced locomotor
hyperactivity, deficits in sensorimotor learning, and startle responses typical of Fmr1 KO mice.
In addition, altered BDNF signaling in FMRP-deficient neural progenitor cells (NPCs) suggested that
perturbations of brain development in FXS occur at very early stages of development [161].
A single-nucleotide polymorphism (SNP) in the human BDNF gene, leading to a methionine
(Met) substitution for valine (Val) at amino acid 66, interferes with the intercellular trafficking and
the activity-dependent secretion of BDNF in cortical neurons. One study found that the Val66Met
BDNF polymorphism associates with epilepsy in a Finnish FXS male [162] but was not confirmed
in a group of 77 patients with FXS [157]. However, a significant association between the BDNF
polymorphism and improvements of several clinical measures was observed in a double-blind
randomized placebo-controlled clinical trial of sertraline in FXS aimed to determine the efficacy of
treatment in young children with FXS [157]. In addition, an open-label study showed a significant
increase in BDNF level after treatment with the GABAA agonist acamprosate [107]. Although more
studies are warranted, these findings point to BDNF genotype as a potential molecular biomarker
in FXS.
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11. Amyloid-β Protein Precursor and Amyloid-β (APP, Aβ)
FMRP protein binds to the coding region of the APP mRNA and results in increased translation of
the encoded product, the amyloid precursor protein (APP), which plays a vital role in the developing
brain during synapse formation, while β-amyloid (Aβ) accumulation, results in synaptic loss and
impaired neurotransmission. APP is processed by β- and γ-secretases to produce amyloid-β (Aβ),
which is the prominent peptide found in the case of Alzheimer’s disease (AD).
A study by Westmark et al. found a 1.7-fold increase APP expression in the Fmr1 KO mouse
versus WT using western blot analysis and showed that the genetic knockdown of one APP allele in the
Fmr1 KO mouse rescued the FXS phenotypes including anxiety, seizures, mGLuR-LTD, and the ratio of
mature versus immature dendritic spines [163]. APP and Aβwere evaluated as blood-based biomarkers
and in a prospective open-label trial of acamprosate in pediatric subjects with FXS-associated autism
spectrum disorder and found that acamprosate treatment significantly reduced sAPP and sAPPα [164].
Although blood levels of APP metabolites may not correlate with brain levels, which is one
of the limitations of these studies, altogether these findings support a role for dysregulated APP
production and processing in FXS and indicate that the APP metabolites may be viable biomarkers for
FXS treatment.
12. Additional Potential Biomarkers
12.1. Ion Channels (CaV)
Voltage-gated ion channels are involved in neural transmission and some recent past studies
showed their involvement in the FXS pathology [165]; more specifically, with the voltage-gated calcium
channels (VGCC) family, namely Cav2.1 and Cav2.2 [166]. Synaptic transmission depends critically on
presynaptic calcium entry via voltage-gated calcium (CaV) channels. FMRP regulates the expression of
neuronal N-type CaV channels (CaV2.2) [166] and dysregulated calcium homeostasis, in addition to the
decreased expression of the pore-forming subunit of the Cav2.1 channel, the Cacna1a gene, in Fmr1-KO
cultured neurons [167]. Their findings indicate that FMRP plays a key role in calcium homeostasis
during brain development; furthermore, the authors suggest that calcium homeostasis could be used
as a cellular biomarker and for the identification of new drugs for target treatment in FXS.
12.2. Glycogen Synthase Kinase-3 (GSK-3)
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase that, when phosphorylated,
regulates a variety of developmental processes, such as cell migration, cell morphology, neurogenesis,
and gliogenesis via interaction with a variety of signaling pathways [168]. The lack of FMRP results in
an abnormal increase in GSK-3β mRNA and protein levels in several regions of the brain [169] of the
Fmr1 KO mouse and in decreased hippocampal neurogenesis that likely contributes to the pathogenesis
of FXS [170].
Several studies have demonstrated that lithium treatment rescued the FXS-associated impairments
sustainable throughout the aging process in the Drosophila model of FXS [54,59]. In addition,
GSK-3 inhibitors and lithium treatment provided the direct evidence of GSK-3 involvement in the
pathology of FXS by reducing audiogenic seizure activity, improved performance on the open field
elevated plus maze and passive avoidance tests [171], improved social defects [172], rescue of the
hippocampus-dependent learning deficits [173], and improved cognitive deficits [174] in the Fmr1 KO
mouse. Additionally, the attenuation of reactive astrocytes, which has been observed in many brain
regions of the Fmr1 KO mouse with lithium treatment, provides further evidence of the involvement of
GSK-3 in FXS [175]. These findings raise the possibility that GSK-3 activity may represent a biochemical
mediator biomarker of impaired cognitive function in FXS and that modulators of its activity may
have potential as therapeutic agents [176].
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12.3. Striatal-Enriched Protein Tyrosine Phosphatase (STEP)
Striatal-enriched protein tyrosine phosphatase (STEP) is a brain-specific tyrosine phosphatase
that plays a significant role in the development of the CNS by regulating dendritic proteins
involved in synaptic plasticity [177,178]. STEP dysregulation is involved in the pathophysiology
of several neuropsychiatric disorders [179], including FXS, likely by dephosphorylating both
NMDARs and AMPARs [177]. While the enhanced activity of mGluRs in the absence of FMRP
upregulates the translation of STEP [178,180,181] in the hippocampus of the Fmr1 KO mouse,
genetic reduction of STEP significantly diminishes some FXS-associated behaviors in Fmr1KO including
seizures and restores select social and nonsocial anxiety-related behaviors [181]. Benzopentathiepin
8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (known as TC-2153) is a newly
discovered STEP inhibitor [182]. A recent study [183] reported that this STEP inhibitor reduces
seizure incidence and hyperactivity, anxiety and improves sociability, electrophysiological deficits
in acute brain slices and spine morphology in Fmr1 KO mouse. These observations suggest that
STEP’s expression and activity could be useful for evaluating the clinical benefits of pharmacological
therapeutic approaches in FXS targeting STEP.
12.4. Plasma Cytokines and Chemokines
Cytokines are the most important mediators of cell–cell communication in the human immune
system. They perform a variety of functions like modulation of the central nervous system (CNS),
brain functioning, and responses to infections or injury. Significant differences in plasma cytokine
and chemokines levels were reported in patients with FXS including a high level of IL-1α, RANTES,
and IP-10 [184]. It is currently unknown if the changes in the cytokine and chemokines are determinant
in the development of FXS and if they occur throughout the lifetime of FXS patients, and therefore,
their potential use as biomarkers needs more investigation.
12.5. Diacylglycerol Kinase Kappa (Dgkκ)
Diacylglycerol kinase kappa (Dgkκ) is a master regulator that controls two critical signaling
pathways involved in protein synthesis. Lack of FMRP in the Fmr1 KO mouse neurons results in the
loss of Dgkκ expression along with mGluR1 receptor-dependent DGK activity, leading to synaptic
plasticity alterations, dendritic spine abnormalities, and behavior disorders. These findings support
the involvement of Dgkκ deregulation in FXS pathology and suggest that overexpression of Dgkκ in
neurons could rescue the dendritic spine defects of the Fmr1 KO mouse. Thus, DGKκ expression levels
could represent a biomarker and targeting DGKκ signaling might provide new therapeutic approaches
for FXS [185].
12.6. MicroRNAs (miRNAs)
MicroRNAs (miRNAs) are known as a class of small noncoding RNA molecules (19–23 nucleotides)
that regulate almost 30% of genes at the post-transcriptional level in eukaryotic organisms [186].
Several studies have provided evidence of miRNA involvement in the pathogenesis of FXS by
identifying and isolating several r(CGG)-derived miRNAs, including miR-fmr1-27 and miR-fmr1-42 in
the zebrafish FXS model [187,188]. Their brain exhibits long dendrites and disconnected synapses,
similar to those found in the human FXS hippocampal–neocortical junction [189]. Further, microarray
analyses of miRNAs associated with FMRP in the Fmr1 KO mouse brain identified miR-125a, miR-125b,
and miR-132, and disruption of the regulating of these miRNA-mediated protein translation results in
early neural development and synaptic physiology [190,191]. Another microarray study [192] in the
Fmr1 KO mouse showed the interaction of miR-34b, miR-340, and miR-148a with the Met 3′ UTR of the
FMR1 gene, suggesting that alterations in the miRNA expression resulted from the absence of FMRP,
could contribute to the molecular pathology of FXS. Enhanced expression of miR-510, located on
chromosome X in the 27.3Xq region, flanking to a fragile X site, was reported in full mutation female
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carriers [193]. Thus, although more studies are necessary to confirm their utility, many pieces of
evidence indicate that miRNAs could be attractive candidate biomarkers in FXS.
13. Conclusions
FXS is a challenging disorder in terms of drug development and clinical implementation.
An extensive preclinical work, carried out in the FXS animal models, has provided ways to improve
the behavior, language, and cognitive ability, but several factors (complex clinical phenotype, genetic
variability, gender differences, and use of multiple medications, limitations in the outcome measures
and of tools) might have contributed to a lack of translation from the preclinical to clinical outcomes.
When looking at the design of the preclinical studies to date, some limitations can be identified. Most of
the FXS research in mammalian model systems is limited to two disease models, the Fmr1 KO mouse
and Fmr1 KO drosophila animal model, but the central issue in using these models is variability and
small effect size of the phenotype particularly in the area of cognitive defects. Moreover, overlapping
phenotypes in these animal models sometimes may lead to over-prediction of the therapeutic potential
of novel drug treatments.
Research to date on FXS has provided us with several potential candidate biomarkers that can,
in principle, be used to assess efficacy; molecular biomarkers are promising, simple, and minimally
invasive diagnostic tools that can objectively measure the biologically relevant effects of targeted
treatments on the underlying molecular defects observed in FXS. However, the current research on
molecular biomarkers in FXS suffers from a number of limitations. FXS is a neurological disorder,
but brain tissue is not easily accessible. Therefore, biomarkers must be developed in a tissue that
can be obtained easily, such as PBMCs, platelets, and fibroblasts. No single consistent molecule or
modification state (i.e., phosphorylation or acetylation) has been reported to be differentially regulated
in FXS patients versus controls consistently across multiple testing sites. Although many molecular
biomarkers have been proposed in FXS (Figure 2), no one is accurate enough as changes according to
disease modifications in a trial setting. No clinical history for any marker is available, and lengthy
expensive processing and time consumption are required to generate test substrates such as primary
fibroblasts (and induced pluripotent stem cells).
In summary, there is an urgent need to establish novel and reliable biomarkers in FXS, particularly
blood-based biomarkers, essential to the development of new treatments. They can provide measures of
disease severity and can be used to develop personalized treatments. Interestingly, when monitored over
time, they can be used to evaluate treatment outcomes and help to identify responders, and therefore
those individuals that following treatment have shown real benefit with phenotype improvements.
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